Know Cancer

forgot password

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp

Phase 3
18 Years
Open (Enrolling)
Actinic Keratosis

Thank you

Trial Information

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp

Inclusion Criteria:

- Willing and able to provide written informed consent for the study

- At least 18 years of age.

- Immunocompetent male or non-pregnant and non-lactating female. Each female subject
of childbearing potential (excluding women who are surgically sterilized or
postmenopausal for at least 2 years), in addition to having a negative urine
pregnancy test at Visit 1/Day 1, must be willing to use an acceptable form of birth
control during the study. For the purpose of this study, the following are considered
acceptable methods of birth control: oral contraceptives, contraceptive patches,
contraceptive implant, vaginal contraceptive, double-barrier methods (for example,
condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device
(IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable
method of birth control if the subject becomes sexually active. Subjects entering
the study who are on hormonal contraceptives (oral contraceptives, patches and
injection) must have been on this method for at least 3 months (90 days) prior to the
study and continue the method for the duration of the study. Subjects who had used
hormonal contraception (oral contraceptives, patches and injection) and stopped must
have stopped no less than 3 months (90 days) prior to baseline. Subjects entering
the study using contraceptive implants and intrauterine contraceptives must have been
on this method for at least 6 months (180 days) and continue for the duration of the
study and if they stopped must have stopped no less than 6 months (180 days) prior to

- Clinical diagnosis of AK, defined as ≥ 5 and ≤ 20 clinically typical, visible or
palpable AK lesions, each at least 4 mm in diameter, in an area that exceeds 25 cm2
on either the face (excluding ears) or balding scalp, but not both face and scalp.

- In general good health and free from any clinically significant disease, other than
AK, that might interfere with the study evaluations.

- Willing and able to understand and comply with the requirements of the study, apply
the IP as instructed, attend the required visits, comply with therapy prohibitions,
and be able to complete the study.

Exclusion Criteria:

- Presence of atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea,
squamous cell carcinoma, or other possible confounding skin conditions on the
treatment area of either the face or balding scalp.

- Clinically significant systemic disease (immunological deficiencies), unstable
medical disorder, life-threatening disease, or current malignancies.

- Use on the face or balding scalp of chemical peel, dermabrasion, laser abrasion,
psoralen plus ultraviolet A (PUVA) therapy, and/or ultraviolet B (UVB) therapy in the
last 6 months (180 days)

- Use of any systemic cancer chemotherapy medications in the last 6 months (180 days)

- Use on the face or balding scalp of cryodestruction or chemodestruction, curettage,
photodynamic therapy, surgical excision, topical 5-fluorouracil, topical
corticosteroids, topical diclofenac, topical imiquimod, topical retinoids,
masoprocol, or other treatments for AK in the last 1 month (30 days)

- Immunomodulators or immunosuppressive therapies, interferon, oral/systemic
corticosteroids, or cytotoxic drugs in the last 1 month (30 days). Intranasal or
inhaled corticosteroids are acceptable if kept constant throughout the study.

- Need or intent to continue to use any treatment listed in the four points above
during the current study

- Known hypersensitivity or allergies to imiquimod or any component of the IP (in any
dosage form).

- Females who are pregnant, breastfeeding, intending to become pregnant during the
study, or who do not agree to use an acceptable form of birth control during the

- Any clinically significant condition or situation other than the condition being
studied that, in the opinion of the investigator, would interfere with the study
evaluations or optimal participation in the study.

- Use of any investigational drug or investigational device within 1 month (30 days)
prior to randomization.

- Previous participation in this study.

- Sunburn in the designated treatment area to be treated at study entry.

- Current involvement in activities that require excessive or prolonged sun exposure.

- Consumption of excessive amounts of alcohol, abuse drugs.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Outcome Measure:

Primary Efficacy Endpoint

Outcome Description:

The primary efficacy endpoint is the proportion of subjects with treatment success at Visit 5/Week 14 (8 weeks post-treatment). Treatment success is defined as 100% clearance of all AK lesions (baseline AK lesions and any new AK lesions) within the treatment area.

Outcome Time Frame:

14 Weeks

Safety Issue:



United States: Institutional Review Board

Study ID:

SYM 2012-01



Start Date:

September 2012

Completion Date:

August 2013

Related Keywords:

  • Actinic Keratosis
  • Keratosis
  • Keratosis, Actinic



Research Across America Carrollton, Texas  75010
Jacksonville Center for Clinical Research Jacksonville, Florida  32216
Omega Medical Research Warwick, Rhode Island  02886
Altman Dermatology Associates Arlington Heights, Illinois  60004
Visions Clinical Research Boynton Beach, Florida  33472
Park Avenue Dermatology, PA 1543 Kingsley Ave, Bldg 1 and 16 Orange Park, Florida  32073
Northern California Research Sacramento, California  95821
Dermatology Research Associates Los Angeles, California  90045
Philadelphia Institute of Dermatology Fort Washington, Pennsylvania  19034
Skin Surgery Medical Group, Inc. San Diego, California  92108
International Dermatology Research, Inc. Miami, Florida  
MedaPhase, Inc. Newman, Georgia  30263
Oregon Medical Research Center, PC Portland, Oregon  97223
Radiant Research, Inc. Chandler, Arizona  85225
Radiant Research, Inc. Akron, Ohio  44311
The Indiana Clinical Trials Center Plainfield, Indiana  46168
Longmont Clinic, PC Longmont, Colorado  80501
Encino Research Center Encino, California  91436
Tampa Bay Medical Research Clearwater, Florida  33761
Tory Sullivan, M.D., P.A. N. Miami Beach, Florida  33162
Leavitt Medical Associates of Florida dba Ameriderm Research Ormond Beach, Florida  32174
Radiant Research, Inc. Pinellas Park, Florida  33781
Dermatology Specialists Research LLC Louisville, Kentucky  40202